Etoflam 5% w/w Gel

দেশ: আয়ার্লণ্ড

ভাষা: ইংরেজি

সূত্র: HPRA (Health Products Regulatory Authority)

সক্রিয় উপাদান:

Etofenamate

থেকে পাওয়া:

Phoenix Labs

এটিসি কোড:

M02AA; M02AA06

INN (আন্তর্জাতিক নাম):

Etofenamate

ডোজ:

5 percent weight/weight

ফার্মাসিউটিকাল ফর্ম:

Gel

প্রেসক্রিপশন টাইপ:

Product subject to prescription which may be renewed (B)

থেরাপিউটিক গ্রুপ:

Anti-inflammatory/analgesic for the treatment of inflammatory musculoskeletal system disorder

থেরাপিউটিক এলাকা:

Antiinflammatory preparations, non-steroids for topical use; etofenamate

থেরাপিউটিক ইঙ্গিত:

For the treatment of inflammatory disorders of the musculoskeletal system.

অনুমোদন অবস্থা:

Marketed

অনুমোদন তারিখ:

1990-04-04

তথ্য লিফলেট

210
ETOFLAM 5% w/w GEL
Package Leaflet: Information for the user
Active Ingredient: Etofenamate
Read all of this leaflet carefully before you start using this
medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to
others. It may harm them,
even if their symptoms are the same as yours.
- If any of the side effects get serious, or if you notice any side
effects not listed in this leaflet,
please tell your doctor or pharmacist.
1. WHAT ETOFLAM GEL IS AND WHAT IT
IS USED FOR:
The name of this medicine is Etoflam 5% w/w
Gel. The gel contains etofenamate as the
active ingredient. Etofenamate belongs to a
class of drugs called nonsteroidal, anti-
inflammatory drugs, which are commonly
used to relieve pain and reduce swelling.
Etoflam 5% w/w Gel is used to relieve pain
and inflammation locally in muscles and soft
tissues. Such pain and inflammation can
occur with sprains, tennis elbow, strains,
rheumatoid arthritis or osteoarthritis and
other similar conditions.
When you apply the gel to your skin, the
etofenamate is readily transported through
your skin and concentrated in the inflamed
area. Here it reduces the inflammation and
eases the pain by preventing the release of
substances in the tissues which cause
inflammation and pain.
2. BEFORE YOU TAKE ETOFLAM 5% W/W
GEL
Do Not use Etoflam 5% w/w Gel:
• If you are allergic (hypersensitive) to any of
the ingredients in Etoflam 5% w/w gel or to
other non-steroidal anti-inflammatory agents
including aspirin
• Etoflam 5% w/w gel contains alcohol and
should not be applied to broken skin
• Etoflam 5% w/w gel should not be used
with tight bandages or dressings, in the
presence of local infection or applied to the
same area where other gels or creams are
being used
Take special care with Etoflam 5% w/w Gel
Etoflam 5% w/w gel is for external use only
and contact with your eyes or other mucus
membranes should be avoided. Hands
should be w

পণ্য বৈশিষ্ট্য

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Etoflam 5% w/w Gel
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
The gel contains 5% w/w etofenamate.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Gel
A nearly transparent yellowish gel.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of inflammatory disorders of the musculo-skeletal
system.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Recommended dosage:
Adults (including the elderly):
Etoflam 5% w/w gel is applied topically. A 5-10cm strip of gel
(according to the area affected) should be rubbed in
gently. This may be repeated up to 4 times daily.
Clinical studies in patients with impaired renal function or
undergoing anti-coagulant therapy have not indicated a need
to change the recommended dosage in these patients.
Children and infants:
The use of Etoflam 5% w/w gel is not recommended in children or
infants.
It is recommended that treatment should be reviewed after 14 days.
Treatment should not extend beyond 6 weeks. In
symptomatic treatment of osteoarthritis, therapy should be reviewed
after 4 weeks.
4.3 CONTRAINDICATIONS
1.
Etoflam 5% w/w gel contains alcohol and should not be applied to
broken skin.
2.
Use with occlusive dressings.
3.
Use in patients hypersensitive to any of the ingredients or to
non-steroidal anti-inflammatory agents including
aspirin.
4.
Use simultaneously to the same site with any other topical
preparation.
5.
Use in the presence of local infection.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_